Job Search
☆ The Japanese corporation from the United States that provides randomization and trial supply management software! ☆
Headquartered in Wellesley, Massachusetts, 4G Clinical is a global leader in randomization, clinical supply management and supply forecasting optimization software for the life sciences industry, providing the only fully cloud-based, 100% configurable and flexible solution leveraging natural language processing to accelerate clinical trials.
4G Clinical's professional staff is humble, confident, curious and driven by a sense of responsibility to get things done.
Most importantly, everyone at 4G Clinical is passionate about our mission to get the medicines people need, faster.
4G Clinical aims to contribute to society by removing technical obstacles in drug development. The first trial was launched in February 2017, and currently there are approximately 500+ trials running simultaneously around the world.
Ed Tourtellotte, CTO of 4G Clinical, was the founder of Tourtellotte Solutions (acquired by Bioclinica), a company specializing in clinical trial consulting and technology. Ed designed and built the world's first configurable IRT in 2000 and also designed the Trident IWR along with the clinical trial delivery simulator tcVisualize. Ed has an incredible ability to attract and retain talented teams and is a frequent speaker at clinical technology conferences. He holds a BA in Economics from Duke University.
Dave Kelleher, CEO of 4G Clinical, was co-founder of ACME Business Consulting (sold to North Highland) and has led major management consulting efforts for some of the largest companies in the Northwest US. Dave was named to the Portland Business Journal's 40 Under 40 Entrepreneurs and was honored by the U.S. Small Business Administration (SBA) as an Oregon Small Business Owner. A former Army Ranger, David was diagnosed with Multiple Sclerosis in his early 20s. He has been active in finding a cure and has served as the board chair of the Oregon chapter of the National Multiple Sclerosis Society and in multiple national roles. Dave holds a BS in Biology from Duke University.
How do we differentiate ourselves? We can launch studies faster than any company in the world. We have proven that many times.
You do not always need speed, but what you always need is flexibility because trials change, and the designs can change.
We typically win on speed and flexibility. We are also the newest offering in the space, so we have the most modern technology stack.
We use natural language processing. That is how we are able to do certain things.
That is how we are processing to read a system specification and configure the study without human intervention.
RTSM technology
Clinical trial design is becoming more complex.
The inability of RTSM technology to keep up with its complexity is hampering faster delivery of medication to patients. First- and third-generation RTSMs have not evolved to support clinical trials these days.
4G Clinical's 4th Generation RTSM addresses the complexity of clinical trial design: technology bottlenecks.
-100% reconfigurable and flexible solution with natural language processing (NLP)-
World's Most Innovative Randomization and Trial Supply Management (RTSM)
-Accelerate clinical trial launch with rapid build, verification, and implementation timelines.
-Agile technology stack improves data quality.
-Prancer RTSM® integrated forecasting capabilities solve complex forecasting challenges.
The world's most dynamic supply and demand planning solution
-Build, run, and validate your supply chain model in minutes instead of days.
-Completely control the effect of input on output to ensure transparency.
-Reduces human error by eliminating manual work.
-Eliminates the need for external SMEs to build, read and analyze supply chain models.
— — —You established the Tokyo office with a view to expanding into the Asia-Pacific region. Can you tell us about the current status of your activities?
We established our base in Japan about three years ago. Most of our competitors do not directly visit Japanese pharmaceutical companies, but instead do business through the R&D centers of pharmaceutical companies in the US or Europe. We thought it was time to go directly to the Japanese market and gain a deeper understanding of the market. We established our base in Japan 7 years ago and we have 26 people working in our Tokyo office, led by our Japan Director, Mr. Kitami.
We hold an event called "Customer Advisory Group" in all four regions where we do business. We have held two in Japan, with a total of about 50 clinical trial sponsors and contract research organizations (CROs) participating. It is an opportunity for our existing and potential customers, as well as companies that may have no contact with us, to gather together and learn about industry trends, and we can also receive feedback on our services and products, so I think these sessions in Japan are particularly significant.